Human research can be useful but narrow. Preclinical research can be informative but preliminary. Ask what was studied, who or what was included and what remains unresolved.
01Published randomized human trials
Tesamorelin
Human evidence exists in a defined population
What the source studied
Randomized trials in adults living with HIV and excess abdominal fat, including a 12-month study of 404 participants and pooled phase 3 reporting.
What it does not establish
These records concern the clinical trial intervention, population and protocol. They do not authenticate or establish outcomes for a separately sourced material.
Clinical development has advanced; the molecule remains investigational
What the source studied
A 48-week phase 2 obesity trial enrolled 338 adults. A 2026 randomized phase 3 trial studied HbA1c and body-weight outcomes over 40 weeks in adults with type 2 diabetes.
What it does not establish
Published phase 3 data do not equal approval. Trial results apply to the sponsor’s controlled intervention—not a separately sourced material.
Published discussion is dominated by laboratory, animal and review literature. Those study types can generate hypotheses but do not answer the clinical questions addressed by adequate randomized human trials.
What it does not establish
Mechanistic plausibility, animal findings and a high-purity COA cannot substitute for human efficacy, safety or regulatory review.
Two randomized, placebo-controlled ascending-dose studies in healthy adults reported pharmacokinetic and growth-hormone / IGF-I measurements over 28 and 49 days.
What it does not establish
Short healthy-volunteer pharmacology studies do not establish disease benefit, long-term safety, or expected results in another population or formulation.
A 72-participant topical ophthalmic phase 2 study examined thymosin β4 solution. TB-500 commonly refers to the LKKTETQ fragment, which is not interchangeable with the full 43-amino-acid peptide studied in that trial.
What it does not establish
A study of one molecular entity, formulation and route cannot be repurposed as evidence for a differently named fragment or product.
Route and formulation determine what the evidence means
What the source studied
Human fibroblast experiments reported changes in collagen synthesis. An older controlled trial evaluated a specific GHK-Cu topical gel alongside standardized care for diabetic neuropathic ulcers.
What it does not establish
Cell-culture and topical-gel findings do not establish the safety or effects of injectable GHK-Cu. FDA notes limited human data for injectable routes.
Endogenous human biology is not an administered-drug trial
What the source studied
A 2021 translational paper combined cell and animal work with exercise sampling in 10 young men, measuring endogenous MOTS-c in muscle and circulation.
What it does not establish
The human component did not administer MOTS-c. FDA reports no identified human exposure data for drug products containing administered MOTS-c.
A central coenzyme is not automatically a validated wellness therapy
What the source studied
A small human pilot tracked plasma and urinary metabolites during a six-hour NAD+ infusion. A 2026 multi-cohort study found whole-blood NAD+ remained stable with age and lifestyle interventions.
What it does not establish
The infusion pilot did not establish clinical efficacy. Blood NAD+ is not a universal measure of tissue status or biological aging.
KPV has been studied in human-derived epithelial cell lines and mouse models of colitis, where investigators measured NF-κB-related signalling, cytokines, histology and recovery.
What it does not establish
FDA reports no identified human exposure data for KPV drug products. Cell and mouse findings cannot establish human efficacy, dose, route or safety.
Glow combines BPC 157, GHK-Cu and TB-500. Klow adds KPV. The named components appear in different cell, animal or formulation-specific research programmes.
What it does not establish
No controlled clinical evidence was identified for either fixed mixture. Component plausibility cannot establish interactions, stability, safety, synergy or benefit.
Research information is not human-use information.
Health Canada states that injectable peptides are generally regulated as prescription drugs in Canada and that “research use only” / “not for human consumption” labelling does not exempt unauthorized products from regulatory requirements. EternaGen provides educational context and batch documentation only—not medical advice, dosing, administration, therapeutic claims or recommendations for human or veterinary use.
